PALB2 and in situ carcinoma: For patients with in situ carcinoma, the BRCA1/2 double mutation frequency was 0.10% (2/2079), and the BRCA1/2 and PALB2 triple mutation frequency was 0.05% (1/2079; Table 5; Figure 2).